SymbioCellTech
BioTech/Drugs - Salt Lake City, UT, US
SymbioCellTech Employees
SymbioCellTech Senior Management
SymbioCellTech Details
SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.
SymbioCellTech Technologies
Email Providers
Gmail
Fonts
Typekit
Tag Management
Google Tag Manager
Other
Mobile Friendly
Analytics and Tracking
Google Analytics